Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Egawa, S.
Right arrow Articles by Baba, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Egawa, S.
Right arrow Articles by Baba, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Japanese Journal of Clinical Oncology 30:21-26 (2000)
© 2000 Foundation for Promotion of Cancer Research

A Pilot Study of Intermittent Androgen Ablation in Advanced Prostate Cancer in Japanese Men

Shin Egawa1, Rikiya Takashima1, Kazumasa Matsumoto1, Hideyuki Mizoguchi1, Sadahito Kuwao2 and Shiro Baba1,+

Departments of 1Urology and 2Pathology, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan

Background: Permanent androgen ablation has been the mainstay of treatment for advanced prostate cancer. However, the favorable outcome seen in recent pilot studies of intermittent androgen ablation raises the possibility of overtreatment.

Methods: This study included 35 Japanese men with advanced prostate cancer. Initial androgen ablation continued for 2 months after PSA levels decreased to <4.0 ng/ml, then was withdrawn. Androgen ablation was reinstituted 2 months after PSA reached levels >10 ng/ml, when indicated clinically or on patient request. Cycling continued until androgen independence was reached.

Results: Mean follow-up was 21.0 months, representing an average of 2.5 cycles. Nine patients developed androgen independence at an average of 16.0 months following androgen ablation; three of these have died. Six of the nine patients with early biochemical progression had elevated alkaline phosphatase levels at entry; five of these exhibited a flare in alkaline phosphatase activity after initiation of androgen ablation. Mean bone mineral density (BMD) in the lumbar spines of 17 patients was 81.5 mg/cm3 at 23 months following therapy. The BMD of 10 of these patients was normal for their age. Four patients suffered bone fractures, none pathological.

Conclusions: Intermittent androgen ablation may be an option for patients with advanced prostate cancer and may be especially beneficial for those with initially low BMD levels. Patients with elevated alkaline phosphatase levels at entry or a flare in its activity may not be ideal candidates. Whether prolonging time to androgen independence will provide benefit remains to be investigated in a randomized, prospective study.

+ For reprints and all correspondence: Shin Egawa, Department of Urology, Kitasato University School of Medicine, 1–15–1 Kitasato, Sagamihara, Kanagawa 228–8555, Japan. E-mail: s-egpro@sa2.so-net.ne.jp


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Endocr Relat CancerHome page
W. Wang, T. Yuasa, N. Tsuchiya, S. Maita, T. Kumazawa, T. Inoue, M. Saito, Z. Ma, T. Obara, H. Tsuruta, et al.
Bone mineral density in Japanese prostate cancer patients under androgen-deprivation therapy
Endocr. Relat. Cancer, December 1, 2008; 15(4): 943 - 952.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.